Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2022

Reconciliation of revenue from segments to consolidated

The following tables present our segment information (in thousands):


	Evolent Health Services		Clinical Solutions		Intersegment Eliminations		Subtotal		Corporate (1)		Consolidated Total
Revenue
For the Three Months Ended June 30, 2022
Total revenue	$	92,796	$	227,603	$	(460)	$	319,939	$	—	$	319,939

For the Three Months Ended June 30, 2021
Total revenue	$	75,323	$	147,194	$	(460)	$	222,057	$	—	$	222,057

	Evolent Health Services		Clinical Solutions		Subtotal		Corporate (1)		Consolidated Total
For the Three Months Ended June 30, 2022
Adjusted EBITDA	$	15,129	$	13,492	$	28,621	$	(6,882)	$	21,739

For the Three Months Ended June 30, 2021
Adjusted EBITDA	$	6,531	$	13,597	$	20,128	$	(6,782)	$	13,346


	Evolent Health Services		Clinical Solutions		Intersegment Eliminations		Subtotal		Corporate (1)		Consolidated Total
Revenue
For the Six Months Ended June 30, 2022
Total revenue	$	200,114	$	417,802	$	(920)	$	616,996	$	—	$	616,996

For the Six Months Ended June 30, 2021
Total revenue	$	160,609	$	277,417	$	(898)	$	437,128	$	—	$	437,128


	Evolent Health Services		Clinical Solutions		Subtotal		Corporate (1)		Consolidated Total
For the Six Months Ended June 30, 2022
Adjusted EBITDA	$	23,346	$	35,688	$	59,034	$	(13,040)	$	45,994

For the Six Months Ended June 30, 2021
Adjusted EBITDA	$	12,473	$	29,573	$	42,046	$	(13,793)	$	28,253

————————

(1)Corporate includes various finance, human resources, legal, executive and other corporate infrastructure expenses.

Reconciliation of Adjusted EBITDA to net loss

The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net loss attributable to common shareholders of Evolent Health, Inc. (in thousands):


	For the Three Months Ended June 30,				For the Six Months Ended June 30,
	2022		2021		2022		2021
Net loss attributable to common shareholders of Evolent Health, Inc.	$	(4,588)	$	(9,107)	$	(9,938)	$	(18,914)
Less:
Interest income	223		68		340		191
Interest expense	(2,148)		(6,274)		(4,389)		(12,611)
Benefit from (provision for) income taxes	184		(91)		(1,018)		(702)
Depreciation and amortization expenses	(15,112)		(14,916)		(30,218)		(30,103)
Gain on transfer of membership	—		—		—		22,969
Loss on repayment of debt, net	—		—		—		(19,158)
Gain from equity method investees	1,952		4,879		2,548		12,662
Change in fair value of contingent consideration	(800)		—		(6,878)		594
Other income (expense), net	297		(18)		475		(32)
Repositioning costs	—		(663)		—		(6,043)
Stock-based compensation expense	(7,012)		(3,653)		(12,358)		(7,359)
Severance costs	—		—		(39)		(52)
Amortization of contract cost assets	(27)		(196)		(54)		(323)
Strategy and shareholder advisory expenses	—		(1,513)		—		(6,513)
Acquisition costs	(3,421)		(76)		(3,878)		(2,070)
Gain (loss) from discontinued operations (1)	(463)		—		(463)		1,383
Adjusted EBITDA	$	21,739	$	13,346	$	45,994	$	28,253

————————

(1)Includes $(0.5) million loss on disposal of discontinued operations for the three and six months ended June 30, 2022 and $1.9 million gain on disposal of discontinued operations for the six months ended June 30, 2021, respectively.